FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20349

	OMB APPROVAL												
-													

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>THANGARAJ IMMANUEL</u>						2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC								5. Relationship of Repor (Check all applicable) X Director			ting Pe	()	Issuer Owner
					_ AC	UR.C)B]								_		۵.		r (specify
(Last)	(Fi	rst) (Middle)												Officer (give titl below)			belov	
10001 W	OODLOCE	H FOREST DRI	VE			3. Date of Earliest Transaction (Month/Day/Year)													
SUITE 175					03/	03/31/2005													
(Chroat)					- 4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) THE														<u> </u>		n filed by C	ne Re	porting Per	son
WOODL	ANDS TX	K 7	77380		_											n filed by M		an One Re	
(City)	(St	rate) (Zip)																
		Tabl	e I - No	on-Deriv	vative	Sec	uritie	s Ac	quired	l, Dis	sposed o	f, or E	Benefic	cially	y Owne	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					Execution Date,					es Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) c (D)	Price	е	Transac	saction(s) 7. 3 and 4)			(instr. 4)	
Common Stock 03/31/2				/2005	005			J ⁽¹⁾		50,832	A	\$0	.61	354	354,452		I	By Essex Woodlands Health Ventures Fund V, L.P. ⁽²⁾	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/I			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exercion Da /Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Instrand 4)		De Se (Ir	Price of erivative ecurity 1str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
		Cod		Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Number of Shares							

Explanation of Responses:

- $1. \ The \ Common \ Stock \ was \ is sued \ as \ a \ quarterly \ interest \ payment \ on \ a \ senior \ secured \ note.$
- 2. The reporting person is a managing director of the general partner of the partnership that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

/s/ Immanuel Thangaraj 04/04/2005

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.